1. Home
  2. VRTX vs SPGI Comparison

VRTX vs SPGI Comparison

Compare VRTX & SPGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$446.83

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Logo S&P Global Inc.

SPGI

S&P Global Inc.

HOLD

Current Price

$424.44

Market Cap

124.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRTX
SPGI
Founded
1989
1860
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Finance: Consumer Services
Sector
Technology
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
115.7B
124.6B
IPO Year
2006
1994

Fundamental Metrics

Financial Performance
Metric
VRTX
SPGI
Price
$446.83
$424.44
Analyst Decision
Buy
Strong Buy
Analyst Count
29
15
Target Price
$539.69
$558.33
AVG Volume (30 Days)
1.1M
1.9M
Earning Date
05-04-2026
04-28-2026
Dividend Yield
N/A
0.90%
EPS Growth
836.54
18.70
EPS
4.02
4.69
Revenue
$2,488,652,000.00
$6,063,000,000.00
Revenue This Year
$10.79
$9.66
Revenue Next Year
$10.47
$7.35
P/E Ratio
$110.02
$89.50
Revenue Growth
46.20
7.10
52 Week Low
$362.50
$381.61
52 Week High
$509.98
$579.05

Technical Indicators

Market Signals
Indicator
VRTX
SPGI
Relative Strength Index (RSI) 56.43 53.07
Support Level $429.02 $416.06
Resistance Level $461.66 $450.12
Average True Range (ATR) 10.08 10.27
MACD 0.78 1.32
Stochastic Oscillator 83.11 78.79

Price Performance

Historical Comparison
VRTX
SPGI

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About SPGI S&P Global Inc.

S&P Global provides data and benchmarks to capital and commodity market participants. Its ratings business is the largest credit rating agency in the world and S&P's largest segment by profitability. S&P's largest segment by revenue is market intelligence, which provides desktop, data and advisory solutions, enterprise solutions, and credit/risk solutions mostly in the financial-services industry. S&P's other segments include energy (formerly commodity insights, this segment includes Platts and other data), mobility (Carfax), and indexes. S&P plans to spin off mobility in 2026.

Share on Social Networks: